<div><div></div><div><span><p><span>Mangoceuticals, Inc. reported first-quarter 2026 results with revenue of $67.9K, down from $109.3K a year earlier, and a net loss attributable to common stockholders of $3.7M; basic and diluted loss per share was $(0.22) for the quarter — a narrower loss than the prior year period. — 10-Q Summary</span></p><p><strong><span>Financial Highlights</span></strong></p><ul><li><span>Revenue was $67.9K for Q1 2026, compared with $109.3K in Q1 2025 (YoY change (37.9%)).</span></li><li><span>Net income: Net loss attributable to Mangoceuticals, Inc. common stockholders was $(3,697,150) for Q1 2026 vs. $(5,133,391) in Q1 2025.</span></li><li><span>Diluted EPS: Basic and diluted loss per share was $(0.22) for Q1 2026 vs. $(1.12) for Q1 2025.</span></li></ul><p><strong><span>Business Highlights</span></strong></p><ul><li><span>Revenue decline reflected the company prioritizing in-house website development and targeted testosterone replacement therapy (TRT) testing prior to full launch.</span></li><li><span>Fulfillment strategy shifted toward increased use of third-party providers, reducing related-party pharmacy spend; Epiq Scripts remains the primary compounder.</span></li><li><span>Continued commercialization of Mango, Grow, Mojo, Slim RDTs and PRIME (oral TRT) with a website relaunch in progress.</span></li><li><span>Operational progress includes completion of the majority of Phase II respiratory studies in 2025 and preparation for Dermytol skin product commercialization planned for Q3 2026.</span></li><li><span>Cost controls included reduced marketing and investor-relations spend and lower G&amp;A and consulting costs, while stock-based compensation increased to conserve cash.</span></li></ul><p><span>Original SEC Filing: </span>MANGOCEUTICALS, INC. [ MGRX ] - 10-Q - May. 19, 2026</p><section><b><span class="heading-JaE7wgR2">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

MGRX

<p>Mangoceuticals, Inc. reported Q1 2026 revenue of $67.9K, down 37.9% from $109.3K in Q1 2025, with a net loss of $3.7M and a diluted EPS of $(0.22). The decline is attributed to a focus on in-house website development and TRT testing. The company is shifting to third-party fulfillment and plans to commercialize new products, including Dermytol in Q3 2026, while implementing cost controls.</p>

TradingView

Mangoceuticals

VG Health

Proshares Ultra Nasdaq Biotech

iShares US Healthcare Providers

Invesco Biotechnology & Genome ETF

SPDR S&P Health

iShares Biotechnology ETF

iShares Global Healthcare

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

SPDR S&P Biotech

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

iShares US Pharma

Health Care Select Sector SPDR

MANGOCEUTICALS, INC. 1Q 2026: Revenue $67.9K, EPS $(0.22) — 10-Q Summary